自身免疫性肝炎发病机制研究进展——聚焦“肠道菌群与免疫系统相互作用”

doi:10.3969/j.issn.1004-583X.2024.02.016

摘要/Abstract

摘要：

自身免疫性肝炎(autoimmune hepatitis, AIH)是一种免疫介导的肝脏实质炎性疾病,目前治疗手段尚有限,且病因和发病机制仍未明确。阐明AIH的发病机制对其防治至关重要。随着“肠-肝轴”学说提出,肠道菌群作为“肠-肝轴”的一个重要变量,被认为在AIH发生和进展中发挥着综合作用。近年来随着分子生物学的发展,免疫调节在AIH中的作用也得到越来越多研究的关注。本文从肠道菌群与免疫调节之间的相互作用方面阐述了AIH的最新研究进展,为进一步阐明AIH的机制提供了新思路。

中图分类号:

R575.1

张晓璐, 李红山. 自身免疫性肝炎发病机制研究进展——聚焦“肠道菌群与免疫系统相互作用”[J]. 临床荟萃, 2024, 39(2): 177-182.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://huicui.hebmu.edu.cn/CN/10.3969/j.issn.1004-583X.2024.02.016

https://huicui.hebmu.edu.cn/CN/Y2024/V39/I2/177

参考文献 60

[1]	Autoimmune hepatitis[J]. Nat Rev Dis Primers, 2018, 4: 18018. doi: 10.1038/nrdp.2018.18 pmid: 29644995
[2]	Liberal R, De Boer YS, Heneghan MA. Established and novel therapeutic options for autoimmune hepatitis[J]. Lancet Gastroenterol Hepatol, 2021, 6(4): 315-326. doi: 10.1016/S2468-1253(20)30328-9 URL
[3]	Cheng Z, Yang L, Chu H. The gut microbiota: A novel player in autoimmune hepatitis[J]. Front Cell Infect Microbiol, 2022, 12: 947382. doi: 10.3389/fcimb.2022.947382 URL
[4]	Wei Y, Li Y, Yan L, et al. Alterations of gut microbiome in autoimmune hepatitis[J]. Gut, 2020, 69(3): 569-577. doi: 10.1136/gutjnl-2018-317836 pmid: 31201284
[5]	Albillos A, De Gottardi A, Rescigno M. The gut-liver axis in liver disease: Pathophysiological basis for therapy[J]. J Hepatol, 2020, 72(3): 558-577. doi: S0168-8278(19)30604-X pmid: 31622696
[6]	Milosevic I, Vujovic A, Barac A, et al. Gut-liver axis, gut microbiota, and its modulation in the management of liver diseases: A review of the literature[J]. Int J Mol Sci, 2019, 20(2):395. doi: 10.3390/ijms20020395 URL
[7]	Medina-Cleghorn D, Nomura DK. Exploring metabolic pathways and regulation through functional chemoproteomic and metabolomic platforms[J]. Chem Biol, 2014, 21(9): 1171-1184. doi: 10.1016/j.chembiol.2014.07.007 URL
[8]	Luan J, Zhang X, Wang S, et al. NOD-like receptor protein 3 inflammasome-dependent IL-1β accelerated conA-induced hepatitis[J]. Front Immunol, 2018, 9: 758. doi: 10.3389/fimmu.2018.00758 pmid: 29692782
[9]	Vuerich M, Wang N, Kalbasi A, et al. Dysfunctional immune regulation in autoimmune hepatitis: From pathogenesis to novel therapies[J]. Front Immunol, 2021, 12: 746436. doi: 10.3389/fimmu.2021.746436 URL
[10]	Kayama H, Okumura R, Takeda K. Interaction between the microbiota, epithelia, and immune cells in the intestine[J]. Annu Rev Immunol, 2020, 38: 23-48. doi: 10.1146/annurev-immunol-070119-115104 pmid: 32340570
[11]	Becattini S, Taur Y, Pamer EG. Antibiotic-induced changes in the intestinal microbiota and disease[J]. Trends Mol Med, 2016, 22(6): 458-478. doi: S1471-4914(16)30007-7 pmid: 27178527
[12]	Rajili'c-Stojanovi'c M, De Vos WM. The first 1000 cultured species of the human gastrointestinal microbiota[J]. FEMS Microbiol Rev, 2014, 38(5): 996-1047. doi: 10.1111/1574-6976.12075 URL
[13]	Terjung B, Söhne J, Lechtenberg B, et al. p-ANCAs in autoimmune liver disorders recognise human beta-tubulin isotype 5 and cross-react with microbial protein FtsZ[J]. Gut, 2010, 59(6): 808-816. doi: 10.1136/gut.2008.157818 pmid: 19951907
[14]	Jia W, Xie G, Jia W. Bile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis[J]. Nat Rev Gastroenterol Hepatol, 2018, 15(2): 111-128. doi: 10.1038/nrgastro.2017.119 pmid: 29018272
[15]	Trivedi PJ, Adams DH. Mucosal immunity in liver autoimmunity: A comprehensive review[J]. J Autoimmun, 2013, 46: 97-111. doi: 10.1016/j.jaut.2013.06.013 pmid: 23891169
[16]	Liwinski T, Casar C, Ruehlemann MC, et al. A disease-specific decline of the relative abundance of bifidobacterium in patients with autoimmune hepatitis[J]. Aliment Pharmacol Ther, 2020, 51(12): 1417-1428. doi: 10.1111/apt.v51.12 URL
[17]	Wang H, Banerjee N, Liang Y, et al. Gut microbiome-host interactions in driving environmental pollutant trichloroethene-mediated autoimmunity[J]. Toxicol Appl Pharmacol, 2021, 424: 115597. doi: 10.1016/j.taap.2021.115597 URL
[18]	Yuksel M, Wang Y, Tai N, et al. A novel “humanized mouse” model for autoimmune hepatitis and the association of gut microbiota with liver inflammation[J]. Hepatology, 2015, 62(5): 1536-1550. doi: 10.1002/hep.27998 URL
[19]	Elsherbiny NM, Rammadan M, Hassan EA, et al. Autoimmune hepatitis: Shifts in gut microbiota and metabolic pathways among egyptian patients[J]. Microorganisms, 2020, 8(7):1011. doi: 10.3390/microorganisms8071011 URL
[20]	Lou J, Jiang Y, Rao B, et al. Fecal microbiomes distinguish patients with autoimmune hepatitis from healthy individuals[J]. Front Cell Infect Microbiol, 2020, 10: 342. doi: 10.3389/fcimb.2020.00342 URL
[21]	Lewis JD, Chen EZ, Baldassano RN, et al. Inflammation, antibiotics, and diet as environmental stressors of the gut microbiome in pediatric crohn's disease[J]. Cell Host Microbe, 2015, 18(4): 489-500. doi: 10.1016/j.chom.2015.09.008 pmid: 26468751
[22]	Vaishnava S, Yamamoto M, Severson KM, et al. The antibacterial lectin regIIIgamma promotes the spatial segregation of microbiota and host in the intestine[J]. Science, 2011, 334(6053): 255-258. doi: 10.1126/science.1209791 pmid: 21998396
[23]	Bouskra D, Brézillon C, Bérard M, et al. Lymphoid tissue genesis induced by commensals through NOD1 regulates intestinal homeostasis[J]. Nature, 2008, 456(7221): 507-510. doi: 10.1038/nature07450
[24]	Kim MH, Kang SG, Park JH, et al. Short-chain fatty acids activate GPR41 and GPR43 on intestinal epithelial cells to promote inflammatory responses in mice[J]. Gastroenterology, 2013, 145(2): 396-406.e1-10. doi: 10.1053/j.gastro.2013.04.056 pmid: 23665276
[25]	Thangaraju M, Cresci GA, Liu K, et al. GPR109A is a G-protein-coupled receptor for the bacterial fermentation product butyrate and functions as a tumor suppressor in colon[J]. Cancer Res, 2009, 69(7): 2826-2832. doi: 10.1158/0008-5472.CAN-08-4466 pmid: 19276343
[26]	Su ZQ, Mo ZZ, Liao JB, et al. Usnic acid protects LPS-induced acute lung injury in mice through attenuating inflammatory responses and oxidative stress[J]. Int Immunopharmacol, 2014, 22(2): 371-378. doi: 10.1016/j.intimp.2014.06.043 URL
[27]	Pradere JP, Troeger JS, Dapito DH, et al. Toll-like receptor 4 and hepatic fibrogenesis[J]. Semin Liver Dis, 2010, 30(3): 232-244. doi: 10.1055/s-0030-1255353 URL
[28]	Guo S, Nighot M, Al-Sadi R, et al. Lipopolysaccharide regulation of intestinal tight junction permeability is mediated by TLR4 signal transduction pathway activation of FAK and MyD88[J]. J Immunol, 2015, 195(10): 4999-5010. doi: 10.4049/jimmunol.1402598 pmid: 26466961
[29]	Kremer M, Hines IN, Milton RJ, et al. Favored T helper 1 response in a mouse model of hepatosteatosis is associated with enhanced T cell-mediated hepatitis[J]. Hepatology, 2006, 44(1): 216-227. pmid: 16799967
[30]	Zhou YQ, Weng XF, Dou R, et al. Betulin from hedyotis hedyotidea ameliorates concanavalin A-induced and T cell-mediated autoimmune hepatitis in mice[J]. Acta Pharmacol Sin, 2017, 38(2): 201-210. doi: 10.1038/aps.2016.102
[31]	Henao-Mejia J, Elinav E, Thaiss CA, et al. Inflammasomes and metabolic disease[J]. Annu Rev Physiol, 2014, 76: 57-78. doi: 10.1146/annurev-physiol-021113-170324 pmid: 24274736
[32]	Bandyopadhyay K, Marrero I, Kumar V. NKT cell subsets as key participants in liver physiology and pathology[J]. Cell Mol Immunol, 2016, 13(3): 337-346. doi: 10.1038/cmi.2015.115 pmid: 26972772
[33]	Xue R, Zhang H, Pan J, et al. Peripheral dopamine controlled by gut microbes inhibits invariant natural killer T cell-mediated hepatitis[J]. Front Immunol, 2018, 9: 2398. doi: 10.3389/fimmu.2018.02398 pmid: 30386344
[34]	Biagioli M, Carino A, Fiorucci C, et al. GPBAR1 functions as gatekeeper for liver NKT cells and provides counterregulatory signals in mouse models of immune-mediated hepatitis[J]. Cell Mol Gastroenterol Hepatol, 2019, 8(3): 447-473. doi: S2352-345X(19)30081-5 pmid: 31226434
[35]	Jaruga B, Hong F, Sun R, et al. Crucial role of IL-4/STAT6 in T cell-mediated hepatitis: Up-regulating eotaxins and IL-5 and recruiting leukocytes[J]. J Immunol, 2003, 171(6): 3233-3244. pmid: 12960353
[36]	Harada K, Isse K, Nakanuma Y. Interferon gamma accelerates NF-kappaB activation of biliary epithelial cells induced by Toll-like receptor and ligand interaction[J]. J Clin Pathol, 2006, 59(2): 184-190. pmid: 16443736
[37]	Wen L, Ley RE, Volchkov PY, et al. Innate immunity and intestinal microbiota in the development of Type 1 diabetes[J]. Nature, 2008, 455(7216): 1109-1113. doi: 10.1038/nature07336
[38]	Frantz AL, Rogier EW, Weber CR, et al. Targeted deletion of MyD88 in intestinal epithelial cells results in compromised antibacterial immunity associated with downregulation of polymeric immunoglobulin receptor, mucin-2, and antibacterial peptides[J]. Mucosal Immunol, 2012, 5(5): 501-512. doi: 10.1038/mi.2012.23 pmid: 22491177
[39]	Petnicki-Ocwieja T, Hrncir T, Liu YJ, et al. Nod2 is required for the regulation of commensal microbiota in the intestine[J]. Proc Natl Acad Sci U S A, 2009, 106(37): 15813-15818. doi: 10.1073/pnas.0907722106 URL
[40]	Rehman A, Sina C, Gavrilova O, et al. Nod2 is essential for temporal development of intestinal microbial communities[J]. Gut, 2011, 60(10): 1354-1362. doi: 10.1136/gut.2010.216259 pmid: 21421666
[41]	Zhao Y, Alonso C, Ballester I, et al. Control of NOD2 and Rip2-dependent innate immune activation by GEF-H1[J]. Inflamm Bowel Dis, 2012, 18(4): 603-612. doi: 10.1002/ibd.21851 pmid: 21887730
[42]	Czaja AJ. Factoring the intestinal microbiome into the pathogenesis of autoimmune hepatitis[J]. World J Gastroenterol, 2016, 22(42): 9257-9278. doi: 10.3748/wjg.v22.i42.9257 URL
[43]	Mizuhara H, O'neill E, Seki N, et al. T cell activation-associated hepatic injury: Mediation by tumor necrosis factors and protection by interleukin 6[J]. J Exp Med, 1994, 179(5): 1529-1537. doi: 10.1084/jem.179.5.1529 pmid: 8163936
[44]	Porrett PM, Yuan X, Larosa DF, et al. Mechanisms underlying blockade of allograft acceptance by TLR ligands[J]. J Immunol, 2008, 181(3): 1692-1699. doi: 10.4049/jimmunol.181.3.1692 pmid: 18641305
[45]	Vuerich M, Harshe R, Frank LA, et al. Altered aryl-hydrocarbon-receptor signalling affects regulatory and effector cell immunity in autoimmune hepatitis[J]. J Hepatol, 2021, 74(1): 48-57. doi: 10.1016/j.jhep.2020.06.044 pmid: 32663496
[46]	Manfredo Vieira S, Hiltensperger M, Kumar V, et al. Translocation of a gut pathobiont drives autoimmunity in mice and humans[J]. Science, 2018, 359(6380): 1156-1161. doi: 10.1126/science.aar7201 pmid: 29590047
[47]	Schiering C, Wincent E, Metidji A, et al. Feedback control of AHR signalling regulates intestinal immunity[J]. Nature, 2017, 542(7640): 242-245. doi: 10.1038/nature21080
[48]	Hang S, Paik D, Yao L, et al. Bile acid metabolites control T(H)17 and T(reg) cell differentiation[J]. Nature, 2019, 576(7785): 143-148. doi: 10.1038/s41586-019-1785-z
[49]	Wang H, Feng X, Yan W, et al. Regulatory T cells in autoimmune hepatitis: Unveiling their roles in mouse models and patients[J]. Front Immunol, 2020, 11: 575572. doi: 10.3389/fimmu.2020.575572 URL
[50]	Arpaia N, Campbell C, Fan X, et al. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation[J]. Nature, 2013, 504(7480): 451-455. doi: 10.1038/nature12726
[51]	Levy M, Kolodziejczyk AA, Thaiss CA, et al. Dysbiosis and the immune system[J]. Nat Rev Immunol, 2017, 17(4): 219-232. doi: 10.1038/nri.2017.7 pmid: 28260787
[52]	Liang M, Liwen Z, Jianguo S, et al. Fecal microbiota transplantation controls progression of experimental autoimmune hepatitis in mice by modulating the TFR/TFH immune imbalance and intestinal microbiota composition[J]. Front Immunol, 2021, 12: 728723. doi: 10.3389/fimmu.2021.728723 URL
[53]	Sebode M, Schulz L, Lohse AW. “Autoimmune(-Like)” drug and herb induced liver injury: New insights into molecular pathogenesis[J]. Int J Mol Sci, 2017, 18(9):1954. doi: 10.3390/ijms18091954 URL
[54]	Grant CR, Holder BS, Liberal R, et al. Immunosuppressive drugs affect interferon (IFN)-γ and programmed cell death 1 (PD-1) kinetics in patients with newly diagnosed autoimmune hepatitis[J]. Clin Exp Immunol, 2017, 189(1): 71-82. doi: 10.1111/cei.12956 pmid: 28257599
[55]	Tiegs G, Hentschel J, Wendel A. A T cell-dependent experimental liver injury in mice inducible by concanavalin A[J]. J Clin Invest, 1992, 90(1): 196-203. doi: 10.1172/JCI115836 pmid: 1634608
[56]	Yang Y, Palm NW. Immunoglobulin A and the microbiome[J]. Curr Opin Microbiol, 2020, 56: 89-96. doi: S1369-5274(20)30099-0 pmid: 32889295
[57]	Pietrzak B, Tomela K, Olejnik-Schmidt A, et al. Secretory IgA in intestinal mucosal secretions as an adaptive barrier against microbial cells[J]. Int J Mol Sci, 2020, 21(23):9254. doi: 10.3390/ijms21239254 URL
[58]	Suzuki K, Maruya M, Kawamoto S, et al. The sensing of environmental stimuli by follicular dendritic cells promotes immunoglobulin A generation in the gut[J]. Immunity, 2010, 33(1): 71-83. doi: 10.1016/j.immuni.2010.07.003 pmid: 20643338
[59]	Peterson DA, Mcnulty NP, Guruge JL, et al. IgA response to symbiotic bacteria as a mediator of gut homeostasis[J]. Cell Host Microbe, 2007, 2(5): 328-339. doi: 10.1016/j.chom.2007.09.013 pmid: 18005754
[60]	Lin H, Lin J, Pan T, et al. Polymeric immunoglobulin receptor deficiency exacerbates autoimmune hepatitis by inducing intestinal dysbiosis and barrier dysfunction[J]. Cell Death Dis, 2023, 14(1): 68. doi: 10.1038/s41419-023-05589-3 pmid: 36709322

自身免疫性肝炎发病机制研究进展——聚焦“肠道菌群与免疫系统相互作用”

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 60

相关文章 15

编辑推荐

Metrics

本文评价

[1]	宋佳亮, 蒋英杰, 孔瑞娜, 蔡青, 高洁. 以IgE和嗜酸粒细胞升高伴多发淋巴结肿大为主要表现的IgG4相关性疾病1例报告[J]. 临床荟萃, 2024, 39(1): 57-60.
[2]	游琪琪, 霍丽娟. 原发性胆汁性胆管炎-自身免疫性肝炎重叠综合征的诊治进展[J]. 临床荟萃, 2024, 39(1): 84-87.
[3]	李阳, 默峰, 辛志飞, 王倩, 邓新娜. 特殊临床表现多系统免疫相关不良事件1例[J]. 临床荟萃, 2023, 38(7): 633-637.
[4]	裴红运, 文洁, 山凤莲. 结核病患者淋巴细胞程序性细胞死亡受体-1表达变化的研究进展[J]. 临床荟萃, 2023, 38(7): 659-662.
[5]	杨小雄, 杨帆, 魏小果. 肠-微生物群-肝轴与代谢相关脂肪性肝病的研究进展[J]. 临床荟萃, 2023, 38(6): 559-563.
[6]	孙星星, 林海. 儿童重症肺炎的免疫功能变化及预后危险因素[J]. 临床荟萃, 2023, 38(6): 521-525.
[7]	程婷婷, 齐彩英, 张雪莲, 肖梦, 隋伟行, 李小燕, 刘建英. 重症肺炎支原体肺炎与血清IgE和C反应蛋白水平的相关性及临床特征[J]. 临床荟萃, 2023, 38(5): 433-437.
[8]	冷婉铜, 陶洁. 多发性骨髓瘤患者治疗后发生静脉血栓栓塞的危险因素[J]. 临床荟萃, 2023, 38(4): 340-345.
[9]	周大伟, 费长东, 刘宇鹏, 张华霖. 获得性免疫缺陷综合征合并重症肺炎1例并文献复习[J]. 临床荟萃, 2023, 38(4): 352-355.
[10]	黄小敏, 赵旭辉, 达德转, 马桃梅, 李红玲. EB病毒感染和程序性死亡受体配体1表达在晚期胃癌免疫靶向治疗中的研究进展[J]. 临床荟萃, 2023, 38(11): 1048-1052.
[11]	何培华, 周幸福, 洪炜鸿, 王利纯, 刘素君, 金玉燕, 曾佳豪, 刘立昌. IgG4相关性肾病4例临床分析[J]. 临床荟萃, 2023, 38(11): 1016-1021.
[12]	王馨雪, 赵丹, 柳惠未, 叶桦, 徐梦丹. 先天免疫反应与非酒精性脂肪性肝病关系的研究进展[J]. 临床荟萃, 2022, 37(9): 846-854.
[13]	王晶霞, 汤灵玲. 肠道微生物群疗法防治复发性艰难梭菌感染研究进展[J]. 临床荟萃, 2022, 37(8): 759-763.
[14]	轩晓倩, 赵君慧, 杨小茜. 炎性指标在非小细胞肺癌患者预后中的临床意义[J]. 临床荟萃, 2022, 37(7): 663-667.
[15]	叶倩, 凌志, 刘申香, 路国涛, 殷旭东. 糖皮质激素对晚期肿瘤患者免疫疗效影响的Meta分析[J]. 临床荟萃, 2022, 37(7): 591-598.